Alliance suspends Oxygent cardiac surgery trial:
This article was originally published in Clinica
Alliance Pharmaceutical has suspended enrolment in a phase III trial of its oxygen-carrying therapeutic, Oxygent, in patients undergoing heart bypass procedures with cardiopulmonary bypass support. The suspension follows an unexpected difference in the incidence of adverse events (AEs), primarily stroke, between the treated patients and the controls. The frequency of AEs in the treatment group was in agreement with published data, but was remarkably low in the control group. The San Diego, California company says the study researchers have not attributed the use of Oxygent to the AEs and that an investigation into the imbalance will be set up.
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.